SEC Filing Analysis: MAIA Biotechnology, Inc. (MAIA)

Executive Summary

• Trading Significance: Low
• Key Takeaway: Director Ramiro Guerrero received an annual/routine grant of 32,012 immediately vesting stock options at an exercise price of $1.18.
• Market Impact: Neutral; routine compensation representing minimal share volume.

Company Information

Field	Value
Company	MAIA Biotechnology, Inc.
Ticker Symbol	MAIA
CIK	0001878313
Industry	Pharmaceutical Preparations [2834]

Insider Information

Field	Value
Name	Guerrero Ramiro
CIK	0001913253
Title/Position	Director
Relationship	Director

Transaction Details

Field	Value
Form Type	4
Transaction Date	2026-09-30
Transaction Code	A (Award/Grant)
Security Type	Stock Options
Shares Involved	32,012
Price Per Share	$0.00 (Exercise price: $1.18)
Total Value	$0.00
Shares Owned After	32,012 options
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$0.00
% of Market Cap	0.00%
Shares Transacted	32,012
% of Shares Outstanding	0.053%
Post-Transaction Ownership	32,012 options (0.053% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: For a micro-cap biotechnology company valued at approximately $70 million, an underlying grant value of roughly $37,774 is standard board-level remuneration.
• Dilution Impact: The grant accounts for approximately 0.053% of the 60.80 million shares outstanding, presenting negligible dilution risk to existing shareholders.
• Transaction Significance: Low significance as an equity award rather than an open-market transaction.

Market Impact Analysis

• Stock Impact Prediction: Neutral. Standard director option compensation does not reflect non-public operational sentiment.
• Sentiment Indicator: Neutral.

Additional Context

• Special Circumstances: Granted pursuant to the 2021 Equity Incentive Plan; options vested 100% immediately on September 30, 2026, expiring in September 2036.